LMAT Lemaitre Vascular (LMAT) Insider Trading, Ownership & Congress Trades
Medical Devices · Surgical & medical instruments & apparatus · CIK 0001158895
Form 144 · 1
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
171
13F, latest reported quarter
Conversions, 180 days
6
Codes C/M, not in net · $598.7K priced
What the filings say about LMAT
Insiders, 180 days
-$6.3M net sold
4 sellers · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$449.2K
1 notice
Lemaitre Vascular insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, LEMAITRE VASCULAR INC insiders sold a net $6.3M of stock across 112 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 46 earlier Form 4 trades (code P or S) here by this insider (46 sales), the last on May 7, 2026.
- The trade is 1.9% of the 1,430,019 shares held after it.
- 3 other insiders sold within 30 days.
- 171 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chairman and CEO LeMaitre George W sold about $3.0M of LMAT on May 8, 2026; 3 other insiders sold within 30 days and 171 funds added in the latest 13F quarter.Context
- 10 earlier Form 4 trades (code P or S) here by this insider (10 sales), the last on Mar 11, 2026.
- The trade is 78.1% of the 3,749 shares held after it.
- 3 other insiders sold within 30 days.
- 171 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Senior V. P., Operations Kamke Trent G sold about $313.3K of LMAT on May 8, 2026; 3 other insiders sold within 30 days and 171 funds added in the latest 13F quarter.Context
- 45 earlier Form 4 trades (code P or S) here by this insider (45 sales), the last on Mar 2, 2026.
- The trade is 1.3% of the 1,457,900 shares held after it.
- 3 other insiders sold within 30 days.
- 171 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chairman and CEO LeMaitre George W sold about $2.0M of LMAT on May 7, 2026; 3 other insiders sold within 30 days and 171 funds added in the latest 13F quarter.Context
- 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on Aug 8, 2025.
- The trade is 128.0% of the 3,942 shares held after it.
- 3 other insiders sold within 30 days.
- 171 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Ross Bridget A sold about $560.4K of LMAT on May 7, 2026; 3 other insiders sold within 30 days and 171 funds added in the latest 13F quarter.Context
- 7 earlier Form 4 trades (code P or S) here by this insider (7 sales), the last on Aug 12, 2025.
- The trade is 83.6% of the 4,714 shares held after it.
- 3 other insiders sold within 30 days.
- 171 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Jasinski Lawrence J sold about $433.7K of LMAT on May 7, 2026; 3 other insiders sold within 30 days and 171 funds added in the latest 13F quarter.112 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$6.3M over 180 days
below 81% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
171 funds bought in last quarter
more than 79% of Medical Devices
Revenue
+13.5% year over year
more than 56% of Medical Devices
Margin
23.1% net margin
more than 94% of Medical Devices
Buybacks
$477.0K repurchased, FY to 2026-06-30
below 90% of Medical Devices
Short interest
8.2% of the float short (float per yahoo 2026-10-26) · 6.9 days to cover · settled 2026-09-30
more than 80% of Medical Devices
What changed in the last 30 days
Oct 28Insider selling stopped: no sales in 90 days after 5 in the prior 90
Why it matters
The absence is the signal: 5 sales in one 90-day window and none in the next is a change of behaviour, not a filing.
Watch LMAT
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-4.6%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns LMAT: institutional holders (13F)
13F holdings, latest reported quarter
3,272,973 sh
$314.1M
1,367,513 sh
$131.2M
1,093,502 sh
$104.9M
963,706 sh
$92.5M
953,437 sh
$91.5M
Congress trades in LMAT
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
LMAT planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
BRIDGET A ROSS
Filed 2026-07-29
$449.2K
LMAT mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
CONESTOGA SMALL CAP FUND
$83.4M position · as of 2026-06-30
4.1%
GRANDEUR PEAK US STALWARTS FUND
$640.2K position · as of 2026-07-31
3.8%
GRANDEUR PEAK GLOBAL EXPLORER FUND
$564.6K position · as of 2026-07-31
3.6%
DAC 3D Dividend Growth ETF
$457.4K position · as of 2026-07-31
2.6%
ABSOLUTE FLEXIBLE FUND
$1.1M position · as of 2026-06-30
2.6%
Congress Small Cap Growth Fund
$47.6M position · as of 2026-07-31
2.4%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
8 registered trials, 5 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
1
Phase 2
0 active
7
Not applicable
5 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2024
$3.2M
$8.3M
$1.1M
+169%
+35%
2020
$1.4M
$3.1M
$598.0K
+14%
+24%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $6.3M sold by insiders over 180 days, 171 funds added last quarter, $449.2K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
LMAT financials
Revenue growth
+13.5%
XBRL, annual
Net margin
23.1%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$262.4M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM LMAT
| FY Dec 2025 | $249.6M |
| FY Dec 2024 | $219.9M |
| FY Dec 2023 | $193.5M |
| FY Dec 2022 | $161.7M |
| FY Dec 2021 | $154.4M |
| Jun 2026 | $70.4M |
| Mar 2026 | $66.6M |
| Dec 2025 | $64.5M |
| Sep 2025 | $61.0M |
| Jun 2025 | $64.2M |
| Mar 2025 | $59.9M |
| Dec 2024 | $55.7M |
| Sep 2024 | $54.8M |
At each fiscal year end
Single quarter
Net margin, TTM
+25.0%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM LMAT
| FY Dec 2025 | +23.1% |
| FY Dec 2024 | +20.0% |
| FY Dec 2023 | +15.6% |
| FY Dec 2022 | +12.8% |
| FY Dec 2021 | +17.4% |
| Jun 2026 | +24.2% |
| Mar 2026 | +23.6% |
| Dec 2025 | +24.1% |
| Sep 2025 | +28.4% |
| Jun 2025 | +21.5% |
| Mar 2025 | +18.4% |
| Dec 2024 | +20.0% |
| Sep 2024 | +20.3% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$73.8M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM LMAT
| FY Dec 2025 | $74.5M |
| FY Dec 2024 | $37.2M |
| FY Dec 2023 | $29.5M |
| FY Dec 2022 | $22.1M |
| FY Dec 2021 | $30.2M |
| Jun 2026 | $13.7M |
| Mar 2026 | $12.3M |
| Dec 2025 | $21.4M |
| Sep 2025 | $26.5M |
| Jun 2025 | $18.9M |
| Mar 2025 | $7.7M |
| Dec 2024 | $13.1M |
| Sep 2024 | $12.6M |
At each fiscal year end
Single quarter
Debt to equity
0.40x
long-term debt only, 2026-06-30; equity 2026-06-30
Debt to equity LMAT
| FY Dec 2025 | 0.43x |
| FY Dec 2024 | 0.50x |
| FY Dec 2023 | 0.00x |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | 0.40x |
| Mar 2026 | 0.42x |
| Dec 2025 | 0.43x |
| Sep 2025 | 0.44x |
| Jun 2025 | 0.46x |
| Mar 2025 | 0.48x |
| Dec 2024 | 0.50x |
| Sep 2024 | 0.00x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.49x
TTM operating cash flow over long-term debt only, 2026-06-30
Cash flow to debt LMAT
| FY Dec 2025 | 0.48x |
| FY Dec 2024 | 0.26x |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | 0.49x |
| Mar 2026 | 0.52x |
| Dec 2025 | 0.48x |
| Sep 2025 | 0.44x |
| Jun 2025 | 0.35x |
| Mar 2025 | 0.29x |
| Dec 2024 | 0.26x |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+16.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity LMAT
| FY Dec 2025 | +15.8% |
| FY Dec 2024 | +13.9% |
| FY Dec 2023 | +10.6% |
| FY Dec 2022 | +7.9% |
| FY Dec 2021 | +12.6% |
| Jun 2026 | +16.8% |
| Mar 2026 | +16.5% |
| Dec 2025 | +15.8% |
| Sep 2025 | +15.0% |
| Jun 2025 | +13.8% |
| Mar 2025 | +13.8% |
| Dec 2024 | +13.9% |
| Sep 2024 | +13.3% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+10.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets LMAT
| FY Dec 2025 | +9.9% |
| FY Dec 2024 | +9.8% |
| FY Dec 2023 | +9.2% |
| FY Dec 2022 | +6.8% |
| FY Dec 2021 | +9.9% |
| Jun 2026 | +10.8% |
| Mar 2026 | +10.5% |
| Dec 2025 | +9.9% |
| Sep 2025 | +10.9% |
| Jun 2025 | +10.0% |
| Mar 2025 | +9.9% |
| Dec 2024 | +9.8% |
| Sep 2024 | +11.6% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+11.2%
operating income after a 22.5% effective tax rate, over long-term debt only, 2026-06-30 plus average of 2025-06-30 and 2026-06-30 minus cash
Return on invested capital LMAT
| FY Dec 2025 | +10.3% |
| FY Dec 2024 | +8.8% |
| FY Dec 2023 | +10.7% |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | +11.2% |
| Mar 2026 | +10.9% |
| Dec 2025 | +10.3% |
| Sep 2025 | +9.6% |
| Jun 2025 | +8.7% |
| Mar 2025 | +8.7% |
| Dec 2024 | +8.8% |
| Sep 2024 | +13.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+13.4%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed LMAT
| FY Dec 2025 | +12.3% |
| FY Dec 2024 | +12.5% |
| FY Dec 2023 | +12.2% |
| FY Dec 2022 | +9.6% |
| FY Dec 2021 | +14.6% |
| Jun 2026 | +13.4% |
| Mar 2026 | +13.0% |
| Dec 2025 | +12.3% |
| Sep 2025 | +13.6% |
| Jun 2025 | +12.4% |
| Mar 2025 | +12.4% |
| Dec 2024 | +12.5% |
| Sep 2024 | +15.2% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
29.58x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing LMAT
| FY Dec 2025 | 32.31x |
| FY Dec 2024 | 47.74x |
| FY Dec 2023 | 42.36x |
| FY Dec 2022 | 49.48x |
| FY Dec 2021 | 39.87x |
| Jun 2026 | 33.67x |
| Mar 2026 | 40.28x |
| Dec 2025 | 32.31x |
| Sep 2025 | 37.88x |
| Jun 2025 | 40.51x |
| Mar 2025 | 42.59x |
| Dec 2024 | 47.74x |
| Sep 2024 | 50.76x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$2.1B
market value at close 2026-10-26 on 2026-08-02 shares, plus long-term debt only, 2026-06-30, minus cash 2026-06-30
Enterprise value LMAT
| FY Dec 2025 | $2.0B |
| FY Dec 2024 | $2.2B |
| FY Dec 2023 | $1.2B |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | $2.3B |
| Mar 2026 | $2.6B |
| Dec 2025 | $2.0B |
| Sep 2025 | $2.1B |
| Jun 2025 | $2.0B |
| Mar 2025 | $2.0B |
| Dec 2024 | $2.2B |
| Sep 2024 | $2.1B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+3.8%
TTM free cash flow over market value at close 2026-10-26
FCF yield LMAT
| FY Dec 2025 | +4.0% |
| FY Dec 2024 | +1.8% |
| FY Dec 2023 | +2.3% |
| FY Dec 2022 | +2.2% |
| FY Dec 2021 | +2.8% |
| Jun 2026 | +3.4% |
| Mar 2026 | +3.2% |
| Dec 2025 | +4.0% |
| Sep 2025 | +3.3% |
| Jun 2025 | +2.8% |
| Mar 2025 | +2.2% |
| Dec 2024 | +1.8% |
| Sep 2024 | +1.6% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
0.76x
P/E over trailing EPS growth of 39%: four quarters to 2026-06-30 against the four to 2025-06-30
PEG, trailing LMAT
| FY Dec 2025 | 1.08x |
| FY Dec 2024 | 1.08x |
| FY Dec 2023 | 0.96x |
| FY Dec 2022 | n/a |
| FY Dec 2021 | 1.88x |
| Jun 2026 | 0.86x |
| Mar 2026 | 1.07x |
| Dec 2025 | 1.08x |
| Sep 2025 | 1.44x |
| Jun 2025 | 1.78x |
| Mar 2025 | 1.40x |
| Dec 2024 | 1.08x |
| Sep 2024 | 0.99x |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $249.6M | $219.9M | $193.5M | $161.7M |
| Gross profit | $178.5M | $150.9M | $127.0M | $104.9M |
| Operating income | $67.9M | $52.3M | $36.7M | $26.8M |
| Net income | $57.7M | $44.0M | $30.1M | $20.6M |
| EPS (diluted) | 2.52 | 1.93 | 1.34 | 0.93 |
| Operating cash flow | $81.3M | $44.1M | $36.8M | $25.4M |
| Cash | $28.2M | $25.6M | $24.3M | $19.1M |
| Long-term debt | $168.6M | $167.8M | $0 | n/a |
| Buybacks | $1.8M | $1.7M | $853.0K | $642.0K |
| Dividends paid | $18.1M | $14.4M | $12.4M | $11.0M |
SEC XBRL, fiscal years, as known on 2026-10-28
LMAT Stock Sonar score 6/7 axes
Find similar shapesCompareLMAT ranks highest on institutional and government (79th percentile) and profitability (77th), and lowest on insider conviction (9th), among Medical Devices peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
LMAT filings, in plain words
Are Lemaitre Vascular insiders buying or selling LMAT?
In the 180 days to 2026-10-28, Lemaitre Vascular insiders were net sellers, a net $6.3M across purchases and sales reported on Form 4, by 4 sellers.
Are there planned insider sales of LMAT?
Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-28, covering $449.2K of stock; the latest, by BRIDGET A ROSS, was filed 2026-07-29.
Read the full summary
In the 180 days to 2026-10-28, Lemaitre Vascular insiders were net sellers of LMAT, a net $6.3M across purchases and sales reported on Form 4 by 4 sellers. None of the 5 insider sales was flagged as made under a Rule 10b5-1 plan. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-28, covering $449.2K of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
